Abstract:<p>Natural products are useful tools for biological mechanism research and drug discovery. Due to the excellent tumor cell growth inhibitory profile and sub-nanomolar potency, Coibamide A (CA), an N-methyl-stabilized depsipeptide isolated from marine cyanobacterium, has been considered as a promising lead compound for cancer treatment. However, the molecular anti-cancer mechanism of the action of CA remains unclear. Here, we showed that CA treatment induced caspase-independent cell death in breast cancer cells. CA treatment also led to severe lysosome defects, which was ascribed to the impaired glycosylation of lysosome membrane protein LAMP1 and LAMP2. As a consequence, the autophagosome-lysosome fusion was blocked upon CA treatment. In addition, we presented evidence that this autophagy defect partially contributed to the CA treatment-induced tumor cell death. Together, our work uncovers a novel mechanism underlying the anti-cancer action of CA, which will promote its further application for cancer therapy.</p>

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to reveal the mechanism of action of the natural product Coibamide A (CA) in cancer treatment. Specifically, the researchers wanted to explore how CA kills cancer cells by inhibiting autophagy. The paper mentions that although CA has a significant inhibitory effect on tumor cell growth and exhibits sub - nanomolar potency in vitro experiments, the specific molecular mechanism of its anticancer effect is still unclear. Therefore, the main purpose of this paper is to clarify whether CA - induced cell death is related to autophagy defects, especially by affecting lysosomal function to achieve this process. ### Main research contents: 1. **Types of CA - induced cell death**: - The study found that CA treatment can induce non - apoptotic cell death in breast cancer cells. - Through flow cytometry and immunoblotting experiments, it was confirmed that CA treatment does not activate Caspase - 3 nor cause changes in the expression of Bcl2 family proteins, indicating that this cell death is non - caspase - dependent. 2. **Impaired lysosomal function**: - CA treatment leads to significant changes in lysosomal morphology and function, including a decrease in the number of lysosomes and an increase in size. - Immunoblotting results showed that CA treatment strongly inhibits the maturation of Cathepsin D, indicating that the lysosomal protein degradation function is impaired. 3. **Inhibition of glycosylation of lysosomal membrane proteins LAMP1 and LAMP2**: - CA treatment significantly reduces the glycosylation of LAMP1 and LAMP2, which may be achieved by inhibiting the function of Sec61a (a core subunit of the endoplasmic reticulum transport complex). - The glycosylation status of these proteins was further verified by PNGase F treatment. 4. **Blocked autophagic flux**: - CA treatment blocks autophagic flux by preventing the fusion of autophagosomes with lysosomes. - Using a pH - sensitive mCherry - GFP - LC3 probe, it was observed that the fusion of autophagosomes with lysosomes was significantly reduced after CA treatment. 5. **Autophagy inhibition partially alleviates CA - induced cell death**: - By knocking down ATG5 (a key component of autophagy), it was found that autophagy inhibition partially alleviates CA - induced cell death, further supporting that the blocked autophagic flux is an important mechanism for CA - induced cell death. ### Conclusion: This paper reveals that CA induces non - caspase - dependent cell death by inhibiting the glycosylation of lysosomal membrane proteins LAMP1 and LAMP2, resulting in impaired lysosomal function and blocked autophagic flux. This finding provides a new mechanistic basis for CA as a potential anticancer drug and is helpful for its further development in clinical applications.

Coibamide A kills cancer cells through inhibiting autophagy

Coibamide A induces mTOR-independent autophagy and cell death in human glioblastoma cells

Novel N -Methylated Cyclodepsipeptide Prodrugs for Targeted Cancer Therapy

Depletion of 4E-Bp1 and Regulation of Autophagy Lead to Yxm110-Induced Anticancer Effects

Coibamide A, a natural lariat depsipeptide, inhibits VEGFA/VEGFR2 expression and suppresses tumor growth in glioblastoma xenografts

Natural Autophagy Blockers, Dauricine (DAC) and Daurisoline (DAS), Sensitize Cancer Cells to Camptothecin-Induced Toxicity

N-Desmethyldauricine Induces Autophagic Cell Death in Apoptosis-Defective Cells Via Ca2+ Mobilization

Autophagy Inhibitor Sensitizes MCF-7 Breast Cancer Cells to Novel Cyclic Tetrapeptide CTS203-induced Caspase-9-dependent Apoptotic Cell Death.

Inhibition of Macroautophagy by Bafilomycin A1 Lowers Proliferation and Induces Apoptosis in Colon Cancer Cells.

Autophagic Vacuole Secretion Triggered by Chidamide Participates in TRAIL Apoptosis Effect in Breast Cancer Cells

Autophagy blockade sensitizes the anticancer activity of CA-4 via JNK-Bcl-2 pathway.

Dichloroacetate Enhances the Antitumor Efficacy of Chemotherapeutic Agents Via Inhibiting Autophagy in Non-Small-cell Lung Cancer

Compound C Induces Protective Autophagy in Human Cholangiocarcinoma Cells Via Akt/mTOR‐independent Pathway

Engineering cannabidiol synergistic carbon monoxide nanocomplexes to enhance cancer therapy<i> via</i> excessive autophagy

Engineering cannabidiol synergistic carbon monoxide nanocomplexes to enhance cancer therapy via excessive autophagy

Cyclovirobuxine D Induces Autophagy-Associated Cell Death Via the Akt/mTOR Pathway in MCF-7 Human Breast Cancer Cells

Caffeic acid phenethyl ester promotes oxaliplatin sensitization in colon cancer by inhibiting autophagy

The marine natural product, dicitrinone B, induces apoptosis through autophagy blockade in breast cancer

Natural small-molecule enhancers of autophagy induce autophagic cell death in apoptosis-defective cells

Carboxyamidotriazole combined with IDO1-Kyn-AhR pathway inhibitors profoundly enhances cancer immunotherapy

Design of Coibamide A Mimetics with Improved Cellular Bioactivity